Type of Assessment:
Diagnostic value of cyclin D1 immunohistochemistry in differentiating malignant mesothelioma from reactive mesothelial proliferation
Annals of Diagnostic Pathology 2025 October [Link] Döndü Nergiz, Arsenal Sezgin Alikanoğlu, Dinç Süren Abstract Introduction: Although morphologic assessment carries utmost importance in differentiating malignant mesotheliomas (MM) from reactive mesothelial proliferations (RMP), sometimes it may fail to clearly differentiate between these two entities. The aim of this study is to evaluate the potential role of…
Read MoreBreaking Through: Immunotherapy Innovations in Pleural Mesothelioma
Clinical Lung Cancer 2025 April 22 [Link] Amalia A Sofianidi, Nikolaos K Syrigos, Kevin G Blyth, Andriani Charpidou, Ioannis A Vathiotis Abstract The prognosis of pleural mesothelioma (PM) is poor and conventional chemotherapy regimens have shown limited antitumor activity. Recent use of immune checkpoint inhibitors (ICIs) has shown promise, with CheckMate-743 trial establishing nivolumab plus…
Read MoreDeoxypodophyllotoxin inhibited the growth of malignant pleural mesothelioma by inducing necroptosis and mitotic catastrophe
Phytomedicine 2025 July 25 [Link] Cheng Zhong, Shenqi Wang, Jingyuan Zhang, Qi Zheng, Yuqiong Lei, Yongle Xu, Tao Ren, Rong Sun Abstract Background: Malignant pleural mesothelioma (MPM) is an extremely aggressive cancer with a poor prognosis and limited effective treatment options. However, recent studies have shown that targeting microtubule regulation is a viable approach for…
Read MoreClinical Significance of Tumor-Infiltrating Lymphocytes in Malignant Peritoneal Mesothelioma: A Single-Center Study of 143 Cases
Annals of Surgical Oncology 2025 July [Link] He-Liang Wu, Rui Yang, Xin-Li Liang, Ru Ma, Yan-Dong Su, Zhi-Ran Yang, Yu-Run Cui, Xue-Mei Du, Yi-Tong Liu, Yan Li Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare malignant tumor with high mortality rate and extremely poor prognosis. The tumor immune microenvironment, particularly tumor-infiltrating lymphocytes (TILs), plays…
Read MoreBAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives
Cancers 2025 May 6 [Link] Susana Cedres, Augusto Valdivia, Ilaria Priano, Pedro Rocha, Patricia Iranzo, Nuria Pardo, Alex Martinez-Marti, Enriqueta Felip Abstract Pleural mesothelioma (PM) is a locally aggressive tumor associated with asbestos exposure. Despite legislative efforts to regulate asbestos use, its incidence continues to rise in some parts of the world. Chemotherapy and immunotherapy…
Read MoreMolecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma
International Journal of Molecular Sciences 2025 May 1 [Link] Taketo Kato, Ichidai Tanaka, Heng Huang, Shoji Okado, Yoshito Imamura, Yuji Nomata, Hirofumi Takenaka, Hiroki Watanabe, Yuta Kawasumi, Keita Nakanishi, Yuka Kadomatsu, Harushi Ueno, Shota Nakamura, Tetsuya Mizuno, Toyofumi Fengshi Chen-Yoshikawa Abstract Mesothelioma is characterized by the inactivation of tumor suppressor genes, with frequent mutations in…
Read MoreUnraveling BOLD-100 synergistic potential in pleural mesothelioma treatment: an in vitro study
Investigational New Drugs 2025 May 8 [Link] Gregorio Bonsignore, Elia Ranzato , Simona Martinotti Abstract Pleural mesothelioma (PM) is a rare cancer affecting the pleural layer on the body’s serosal surfaces. Exposure to asbestos fibers, a naturally occurring fibrous material with insulating characteristics, contributes to PM’s prevalence. PM has a long latency period, making major…
Read MorePD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
Cancer Research Communications 2025 May 1 [Link] Gwendolyn M Cramer, Richard W Davis 4th, Emmanouil Papasavvas, Astero Klampatsa, Joann M Miller, Shirron Carter, Ruth Ikpe, Min Yuan, Sandy Widura, R Sonali Majumdar, Sally McNulty, Mary Putt, Andrew V Kossenkov, Luis J Montaner, Sunil Singhal, Edmund K Moon, Steven M Albelda, Keith A Cengel, Theresa M…
Read MoreEnhanced Detection of Recurrent Diffuse Malignant Peritoneal Mesothelioma Using 68 Ga-FAPI PET/CT Compared to 18 F-FDG PET/CT: A Case Report
World Journal of Nuclear Medicine 2025 March 12 [Link] Marwah Abdulrahman, Ula Al-Rasheed, Ali Dabous, Akram Al-Ibraheem Abstract Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive subtype of epithelioid mesothelioma that arises from the lining of the abdominal cavity. While the applications of traditional fluorine-18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography…
Read MoreOncological Outcomes Of Radical Surgery With And Without Induction And Adjuvant Chemotherapy In Mesothelioma Patients – 8-Year Experience In A Single Center
Portuguese Journal of Cardiac Thoracic & Vascular Surgery 2025 April 29 [Link] Agata Nawojowska, Samuel Mendes, Marion Gaspar, Daniel Cabral, Cristina Rodrigues, Mariana Antunes, Magda Alvoeiro, Telma Calado, Francisco Félix Abstract Introduction: Mesothelioma is a devastating, insidious disease with a long latency period. Its peak incidence occurs in the 5th and 6th decades of life,…
Read More
Skip to content